BrightSpire Capital, Inc. Announces First Quarter 2023 Earnings Results and Conference Call Date

BrightSpire Capital, Inc. Announces First Quarter 2023 Earnings Results and Conference Call Date

NEW YORK–(BUSINESS WIRE)–
BrightSpire Capital, Inc. (NYSE: BRSP) (“BrightSpire Capital” or the “Company”) today announced it will release first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023. The Company will conduct a conference call to discuss the results the same day at 10:00 a.m. ET/ 7:00 a.m. PT.

To participate in the event by telephone, please dial (877) 407-0784 ten minutes prior to the start time (to allow time for registration). International callers should dial (201) 689-8560. The call will also be broadcast live over the Internet and can be accessed on the ‘Shareholders’ section of the Company’s website at www.brightspire.com. A webcast of the call will be available for 90 days on the Company’s website.

For those unable to participate during the live call, a replay will be available starting May 3, 2023 at 1:00 p.m. ET / 10:00 a.m. PT, through May 10, 2023, at 11:59 p.m. ET / 8:59 p.m. PT. To access the replay, dial (844) 512-2921 and use conference ID code 13737277. International callers should dial (412) 317-6671 and enter the same conference ID.

About BrightSpire Capital, Inc.

BrightSpire Capital, Inc. (NYSE: BRSP) is internally managed and one of the largest publicly traded commercial real estate (CRE) credit REITs, focused on originating, acquiring, financing and managing a diversified portfolio consisting primarily of CRE debt investments and net leased properties predominantly in the United States. CRE debt investments primarily consist of first mortgage loans, which we expect to be the primary investment strategy. BrightSpire Capital is organized as a Maryland corporation and taxed as a REIT for U.S. federal income tax purposes. For additional information regarding the Company and its management and business, please refer to www.brightspire.com.

Investor Relations

BrightSpire Capital, Inc.

Addo Investor Relations

Anne McGuinness

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Construction & Property Professional Services REIT Finance

MEDIA:

Logo
Logo

PROCEPT BioRobotics to Report First Quarter 2023 Financial Results on April 27, 2023 and Present at the Bank of America 2023 Health Care Conference in Las Vegas

REDWOOD CITY, Calif., April 05, 2023 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2023 before market open on Thursday, April 27, 2023. The Company’s management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

Members of management will also be presenting at the upcoming Bank of America 2023 Health Care Conference in Las Vegas. Management is scheduled to present on Wednesday, May 10 at 4:20 p.m. Pacific Time.

Live audio of each webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com.

Archived recordings will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. Each webcast will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:

Matt Bacso, CFA
VP, Investor Relations and Business Operations
[email protected]



DynaEnergetics Successfully Defends Itself in Patent Infringement Case

BROOMFIELD, Colo., April 05, 2023 (GLOBE NEWSWIRE) — DynaEnergetics, a business of DMC Global Inc. (Nasdaq: BOOM) today announced it has successfully defended itself in an alleged infringement of Patent No. 9,810,035 (“035 patent”). The case was brought by Repeat Precision, LLC, which alleged DynaEnergetics’ DS MicroSet® setting tool infringed upon the 035 patent. In a trial held in the U.S. District Court for the Western District of Texas, the jury found DynaEnergetics’ product did not infringe on the 035 patent, and no damages were awarded.

“We are encouraged by the jury’s decision and appreciate their consideration of the facts in this case,” said Ian Grieves, president of DynaEnergetics. “Innovation is at the core of DynaEnergetics’ success, and the verdict confirms our MicroSet product is indeed unique.”

The disposable DS MicroSet setting tool is deployed in horizontal oil and gas wells and is used to set a plug at the end of a perforating string. DS MicroSet is a seamless extension of DynaEnergetics’ DS perforating systems and is enabled by DynaEnergetics’ IS2 Intrinsically Safe™ initiating system.

About DynaEnergetics

DynaEnergetics, a business of DMC Global Inc., provides innovative perforating systems that make a measurable impact on well productivity, completion cost and safety. As the only global perforating manufacturer that designs, manufactures and qualifies all of its equipment and accessories in-house, DynaEnergetics ensures unmatched performance and the lowest total cost of operations. For more information, visit www.dynaenergetics.com.

About DMC Global Inc.

DMC Global is an owner and operator of innovative, asset-light manufacturing businesses that provide unique, highly engineered products and differentiated solutions. DMC’s businesses have established leadership positions in their respective markets and consist of: Arcadia, a leading supplier of architectural building products; DynaEnergetics, which serves the global energy industry; and NobelClad, which addresses the global industrial infrastructure and transportation sectors. DMC’s businesses are led by experienced, strategically focused management teams, which are supported with business resources and capital allocation expertise to advance their operating strategies and generate the greatest returns. Based in Broomfield, Colorado, DMC trades on Nasdaq under the symbol “BOOM.” For more information, visit: HTTPS://WWW.DMCGLOBAL.COM/.

CONTACT:

Ian Grieves
President
DynaEnergetics
+49.2241.1236.770
[email protected]

INVESTOR CONTACT:

Geoff High
Vice President of Investor Relations
303-604-3924



Parsons Awarded Fourth Nunn-Perry Award for DoD Mentor-Protégé Program

CENTREVILLE, Va., April 05, 2023 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) received its fourth Nunn-Perry Award from the Department of Defense (DOD) Mentor Protégé Program for demonstrating excellence in teamwork with KODA Technologies to support the warfighter by delivering capabilities across major defense programs. The pair was recognized for their work to support the Missile Defense Agency (MDA) at the DOD Mentor Protégé Summit, held on March 30 in Orlando, Florida.

“The goals of our mentor protégé agreement with KODA Technologies focused on project management, business strategy, business development, approved accounting systems, technology transfer, and the curation of a test concept development lab and associated toolkit,” said William Clark, project manager for Parsons Defense and Intelligence sector. “The Parsons team takes pride in being a strong industry partner to work with and we are thrilled that this partnership resulted in KODA’s first prime contract awarded by the MDA. We look forward to the continued sharing of best practices and technology development to help them be successful.”

Additional achievements realized through the Parsons and KODA Technologies Mentor Protégé agreement include, the development of a new Defense Contract Accounting Agency (DCAA) accounting system and two digital engineering, modeling and simulation technical labs supporting MDA, Army, and Navy projects.

“As a direct outcome of this program, KODA’s new lab and upgraded modeling and simulation capability are already providing value to multiple customers in the missile defense, hypersonics, and space domains by developing innovative concepts for flight test design, launch vehicle instrumentation, and space-debris mitigation. With these enhancements to our existing technical capability and the program’s additional investment in our operations infrastructure, we are postured to be a key contributor in national-priority technology and modernization projects going forward,” said KODA Technologies founder and CEO Julie Schumacher. “We thank the Office of the Secretary of Defense, MDA and our mentor, Parsons, for the difference you’ve made in our company’s growth and future.”

The DOD Mentor Protégé Nunn-Perry Award is named for the contributions of Senator Sam Nunn and former Secretary of Defense William Perry, who played critical roles in the implementation of the DOD Mentor Protégé Program. Established in 1990, the program assists DOD prime contractors in meeting small, disadvantaged business subcontracting goals. The program has since expanded, providing developmental assistance to women-owned small businesses, service-disabled veteran-owned small businesses, and others.

To learn more about Parsons defense capabilities, please visit parsons.com/national-security/.


About Parsons:


Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and intelligence, space and missile defense, transportation, environmental remediation, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn and Facebook to learn how we’re making an impact.


About KODA Technologies:


KODA provides engineering and analytical services that support advanced technology development and modernization for defense and civil space programs. KODA specializes in systems engineering, integration, and testing for aerospace systems, using advanced methods such as digital / model-based engineering. Please visit

www.kodatech.com

and LinkedIn to learn more about our capabilities and current career opportunities.

Media Contact:
Angie Benfield
+1 803.334.5277
[email protected]

Investor Relations Contact:
Dave Spille
+ 1 703.775.6191
[email protected]



Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference

Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference

FREMONT, Calif.–(BUSINESS WIRE)–
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19 at 3:00 p.m. Eastern Time.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and Twitter.

Investor Relations Contact:

Caroline Corner

[email protected]

415-202-5678

Media Contact:

Jennifer Temple

[email protected]

www.personalis.com

650-752-1300

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Oncology Health Hospitals General Health Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted six employees nonqualified stock options to purchase 232,000 shares of its common stock with an exercise price of $3.05 per share, which is equal to the closing price of Kezar’s common stock on April 3, 2023, the grant date of the awards. The stock options were granted as an inducement award material to the individuals entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options will vest over a four-year period, with 25% of each option vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date. The options are subject to the terms and conditions of Kezar’s 2022 Inducement Plan and the stock option agreement covering the grants.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor that has completed a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.

Investor Contact:

Gitanjali Jain

Vice President, Investor Relations and External Affairs

[email protected]

Media Contact:

Julia Deutsch

Solebury Strategic Communications

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Oncology General Health Health Clinical Trials

MEDIA:

Logo
Logo

ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – NBTB, FRBA, MPB, TCRR

NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) — Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

  • NBT Bancorp Inc. (NASDAQ: 

    NBTB

    ) relating to its proposed merger with Salisbury Bancorp, Inc. Under the terms of the merger, Salisbury shareholders will receive 0.745 shares of NBT per share they own. Click here for more information: https://www.monteverdelaw.com/case/nbt-bancorp-inc. It is free and there is no cost or obligation to you.

  • First Bank (NASDAQ


    FRBA

    ), relating to its proposed acquisition of Malvern Bancorp. Under the terms of the agreement, Malvern shareholders will receive 0.7733 shares of FRBA and $7.80 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/first-bank. It is free and there is no cost or obligation to you.

  • Mid Penn Bancorp, Inc. (NASDAQ: 


    MPB


    ), relating to its proposed acquisition of Brunswick Bancorp. Under the terms of the agreement, Brunswick shareholders are expected to receive either 0.598 shares of Mid Penn common stock or $18.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/mid-penn-bancorp-inc. It is free and there is no cost or obligation to you.
  • TCR² Therapeutics Inc. (NASDAQ:

    TCRR

    ), relating to its proposed sale to Adaptimmune Therapeutics plc. Under the terms of the agreement, TCRR shareholders are expected to receive 1.5117 shares of Adaptimmune per share they own. Click here for more information: https://www.monteverdelaw.com/case/tcr2-therapeutics-inc. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and iscommitted to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013 and 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2020 Top Rated Lawyer. Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2023 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.



STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, SAL, ADAP, BRBW

NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) — Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

  • Malvern Bancorp, Inc. (NASDAQ:

    MLVF

    ), relating to its proposed acquisition by First Bank. Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/malvern-bancorp-inc. It is free and there is no cost or obligation to you.
  • Salisbury Bancorp, Inc. (NASDAQ:

    SAL

    ), relating to its proposed merger NBT Bancorp, Inc. Under the terms of the merger, SAL shareholders will receive 0.745 shares of NBT per share they own. Click here for more information: https://www.monteverdelaw.com/case/salisbury-bancorp-inc. It is free and there is no cost or obligation to you.
  • Adaptimmune Therapeutics plc (NASDAQ:

    ADAP

    ), relating to its proposed merger with TCR² Therapeutics Inc. Under the terms of the agreement, ADAP shareholders are expected to own approximately 75% of the combined company. Click here for more information: https://www.monteverdelaw.com/case/adaptimmune-therapeutics-plc. It is free and there is no cost or obligation to you.
  • Brunswick Bancorp (OTC:

    BRBW

    ), relating to its proposed acquisition by Mid Penn Bancorp, Inc. Under the terms of the agreement, BRBW shareholders are expected to receive either 0.598 shares of Mid Penn common stock or $18.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/brunswick-bancorp. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and iscommitted to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013 and 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2020 Top Rated Lawyer. Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2023 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

 



SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – CNXC, ROCC, UNVR, CVT

NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) — Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

  • Concentrix Corp. (NASDAQ:

    CNXC

    ), relating to its proposed merger with Webhelp. Under the terms of the agreement, CNXC shareholders are expected to own approximately 78% of the combined company. Click here for more information: https://www.monteverdelaw.com/case/concentrix-corp. It is free and there is no cost or obligation to you.
  • Ranger Oil Corp. (NASDAQ:

    ROCC

    ), relating to its proposed sale to Baytex Energy Corp. Under the terms of the agreement, ROCC shareholders are expected to receive 7.49 shares of Baytex and $13.31 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/ranger-oil-corp. It is free and there is no cost or obligation to you.
  • Univar Solutions Inc. (NYSE:

    UNVR

    ), relating to its sale to affiliates of Apollo Global Management, Inc. Under the terms of the agreement, UNVR shareholders will receive $36.15 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/univar-solutions-inc. It is free and there is no cost or obligation to you.
  • Cvent Holding Corp. (NASDAQ:

    CVT

    ), relating to its sale to equity funds managed by Blackstone Inc. Click here for more information: https://www.monteverdelaw.com/case/cvent-holding-corp. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and iscommitted to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013 and 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2020 Top Rated Lawyer. Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2023 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.



STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – PTRS, TIG, FOCS, INDT

NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) — Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

  • Partners Bancorp. (NASDAQ:

    PTRS

    ), relating to its proposed sale to LINKBANCORP, Inc.. Under the terms of the agreement, PTRS shareholders are expected to receive 1.15 shares of LINKBANCORP stock per share they own. Click here for more information: https://www.monteverdelaw.com/case/partners-bancorp. It is free and there is no cost or obligation to you.
  • Trean Insurance Group, Inc. (NASDAQ:

    TIG

    ), relating to its proposed acquisition by affiliates of Altaris, LLC. Under the terms of the agreement, TIG shareholders are expected to receive $6.15 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/trean-insurance-group-inc. It is free and there is no cost or obligation to you.
  • Focus Financial Partners Inc. (NASDAQ:

    FOCS

    ), relating to its proposed sale to affiliates of Clayton Dubilier & Rice LLC. Under the terms of the agreement, FOCS shareholders are expected to receive $53.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/focus-financial-partners-inc. It is free and there is no cost or obligation to you.
  • INDUS Realty Trust, Inc. (NASDAQ:

    INDT

    ), relating to its proposed sale to affiliates of Centerbridge Partners, L.P. and GIC Real Estate, Inc.. Under the terms of the agreement, INDT shareholders are expected to receive $67.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/indus-realty-trust-inc. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and iscommitted to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013 and 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2020 Top Rated Lawyer. Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2023 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.